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22q11.2 deletion syndrome (22q11.2DS) is a common genetic disorderwith enormous
phenotypic heterogeneity. Despite the established prevalence of developmental and
neuropsychiatric issues in this syndrome, its neuroanatomical correlates are not as
well understood. A retrospective chart review was performed on 111 patients
diagnosed with 22q11.2DS. Of the 111 patients, 24 with genetically confirmed
22q11.2 deletion and brain MRI or MRA were included in this study. The most
common indications for imaging were unexplained developmental delay (6/24),
seizures of unknown etiology (5/24), and unilateral weakness (3/24). More than half
(13/24) of the patients had significant radiographic findings, including persistent
cavum septi pellucidi and/or cavum vergae (8/24), aberrant cortical veins (6/24),
polymicrogyria or cortical dysplasia (4/24), inner ear deformities (3/24), hypoplastic
internal carotid artery (2/24), and hypoplastic cerebellum (1/24). These findings
reveal the types and frequencies of brain malformations in this case series, and
suggest that the prevalence of neuroanatomical abnormalities in 22q11.2DS may be
underestimated. Understanding indications for imaging and frequently encountered
brain malformations will result in early diagnosis and intervention in an effort to
optimize patient outcomes.
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1 | INTRODUCTION
22q11.2 deletion syndrome (22q11.2DS) is a common genetic disorder
with an estimated incidence of 1 in 4,000 live births (Goodship, Cross,
LiLing, & Wren, 1998; Óskarsdóttir, Vujic, & Fasth, 2004; Tezenas Du
Montcel, Mendizabai, Ayme, Levy, & Philip, 1996). It is often referred
to as velocardiofacial syndrome (VCFS), and is associated with the
phenotype the name suggests—palatal dysfunction, conotruncal heart
defects, and characteristic facies. While these are often the most
recognized findings, 22q11.2 deletion is associated with enormous
phenotypic heterogeneity; over 180 features have been described
(Robin & Shprintzen, 2005).
Approximately 93% of 22q11.2 deletions arise de novo
(McDonald-McGinn & Zackai, 2008). The remaining 7% have an
autosomal dominant inheritance pattern. A hemizygous deletion is
sufficient to produce the full syndrome, but the size and extent of
the deletion has not correlated well with clinical expression. The
deletion site is flanked by low-copy repeats whose high homology to
one another makes this region especially susceptible to rearrange-
ment from unequal meiotic crossovers and non-allelic homologous
recombination (Edelmann, Pandita, & Morrow, 1999). Most patients
(85%) have an approximate 3-Mb deletion encompassing 45
functional genes, 8% have a 1.5-Mb deletion, and the remainderLauren A. Bohm and Tom C. Zhou contributed equally to this work.
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have variable deletion sizes (Emanuel, 2008). Since 1992, fluores-
cence in situ hybridization (FISH) studies using TUPLE1 and N25
probes have allowed clinical laboratories to identify patients with the
22q11.2 deletion, which is almost always too small to be identified
by conventional cytogenetic studies. The probe is limited to one
single target sequence within the 22q11.2 deletion region, and
atypical deletions may not include the region specific to the probe.
Other more sensitive techniques include array comparative genomic
hybridization (aCGH) and single nucleotide polymorphism (SNP)
array.
Management of patients with 22q11.2DS requires coordi-
nated multidisciplinary care, and guidelines on management are
available (Bassett et al., 2011; Fung et al., 2015). While many of
the life-threatening features of 22q11.2DS are addressed in
infancy, the potential for developmental delay, learning disabil-
ities, behavioral impairment and psychiatric illness require
continued surveillance and therapy into adulthood. 22q11.2DS
is the second most common genetic cause of developmental delay
and accounts for 2.4% of individuals with developmental
disabilities (Rauch et al., 2006). Motor and speech-language
delays are commonly observed during early childhood; while
specific learning disabilities are often identified in primary school
ages (Swillen & McDonald-McGinn, 2015). The cognitive capabili-
ties of patients with 22q11.2DS are highly variable. The majority
of affected individuals demonstrate borderline intellectual levels,
and 40% demonstrate mild to moderate intellectual disability
(De Semdt et al., 2007).
In addition, patients with 22q11.2DS are at notably higher risk of
behavioral and psychiatric manifestations, including attention deficit
hyperactivity disorder, autism spectrum disorder, bipolar disorder,
depression, anxiety, obsessive compulsive disorder, and schizophrenia
(Kobrynski & Sullivan, 2007). Studies suggest 9–50% of 22q11.2DS
patients develop behavioral or psychiatric problems at some point in
their lifetime (Kobrynski & Sullivan, 2007). The study of 22q11.2DS
thus offers a unique opportunity to understand the neuroanatomical
differences of certain mental health disorders as they relate to
genetics.
Studies of patients with 22q11.2DS have demonstrated a
range of neuroanatomical abnormalities. Qualitative studies have
reported increased prevalence of developmental midline anoma-
lies (e.g., abnormalities of the septi pellucidi, agenesis of the
corpus callosum) (Campbell et al., 2006; Chow et al., 1999;
Kraynack, Hostoffer, & Robin, 1999; Ryan et al., 1997; Van
Amelsvoort et al., 2001), polymicrogyria (Bingham, Lynch,
McDonald-McGinn, & Zackai, 1998; Cramer, Schaefer, &
Krishnamoorthy, 1996; Ghariani et al., 2002; Kawame, Kurosawa,
Akatsuka, Ochiai, & Mizuno, 2000; Robin et al., 2006), increased
white matter hyperintensities (Campbell et al., 2006; Mitnick,
Bello, & Shprintzen, 1994; Van Amelsvoort et al., 2001),
hippocampal malrotation (Andrade, Krings, Chow, Kiehl, & Bassett,
2013), ventricular enlargement (Chow et al., 1999), hypoplastic
cerebellar vermis and cerebellar atrophy (Bish et al., 2006; Lynch
et al., 1995; Mitnick et al., 1994; Van Amelsvoort et al., 2001).
Quantitative studies using brain MRI have further noted a
decrease in total brain volume by 8.5–11% (Eliez, Schmitt, White,
& Reiss, 2000; Kates et al., 2004; Simon et al., 2005) and multiple
regional changes, such as increased size of caudate nucleus and
insula, and decreased amygdala size (DeBoer, Wu, Lee, & Simon,
2007; Eliez, Barnea-Goraly, Schmitt, Liu, & Reiss, 2002;
Jalbrzikowski et al., 2013). Clinically, nearly 50% of 22q11.2DS
patients have microcephaly (Barnea-Goraly, Eliez, Menon,
Bammer, & Reiss, 2005; Campbell et al., 2006). The cellular
mechanisms leading to these changes have yet to be elucidated.
While there has been some progress in identifying brain
malformations in patients with 22q11.DS, it is unclear how frequently
brain abnormalities are present in the 22q11.2DS population.
Furthermore, the implications of those brain malformations in the
22q11.2DS population as a whole remain unclear. This paper reviews
patients with 22q11.2DS and brainMRI/MRA, who presented to clinic
for multidisciplinary care.
2 | MATERIALS AND METHODS
This study is a retrospective chart review from a tertiary children’s
hospital. Institutional Review Board approval and HIPAA waiver were
obtained from Children’s Minnesota. Patients who presented at the
VCFS Clinic from April 14, 2009 to May 1, 2014 were reviewed within
the Children’s Minnesota electronic medical record.
One hundred eleven consecutive patients presenting to the VCFS
Clinic were identified as potential patients for the study. Of those
patients, 26 had a documented brain MRI or MRA. One patient had a
brain MRI performed and stored at an outside institution, and image
results could not be obtained. Another patient had clinical features of
22q11.2DS, but both FISH and aCGH were negative for 22q11.2
deletion. These two patients were excluded from the study. Therefore,
a total of 24 patients with brainMRI orMRA reports available and only
those with confirmed 22q11.2 deletions by FISH using TUPLE1 probe
or by aCGH were included.
The medical records of the 24 patients were reviewed and data
was collected on developmental history, seizures, head circumfer-
ence, and medical comorbidities. In the analysis, medical comorbid-
ities were categorized using the grouping in the practical guidelines
for multidisciplinary management of 22q11.2DS (Bassett et al.,
2011) as a reference. Clinical judgment was utilized to categorize
medical comorbidities that were not specifically addressed in the
guidelines. A patient was defined as having macrocephaly or
microcephaly if the head circumference at any point during
development was greater than or equal to two standard deviations
above (≥97.5 percentile) or below (≤2.5 percentile) the mean,
respectively.
Original imaging scans were available in 19 of the 24 patients, and
a single pediatric neuroradiologist (R.J.P.) independently reviewed all
these images. For the remaining five patients, the results of the imaging
report as dictated by the original reading radiologist were used. All
institutional imaging was obtained using a GE 1.5 Tesla MRI with a
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standard sequencing protocol, which includes sagittal T1, axial and
coronal fast spin echo T2, axial FLAIR and axial diffusion-weighted
images. For patients with multiple brain MRIs/MRAs, the latest
imaging was used to identify brain malformations because pathology is
more likely to be identified in a more developed brain (e.g.,
myelination). However, in these patients, the indication for obtaining
the first imaging was recorded.
3 | RESULTS
This series of 24 patients was comprised of 14 males and 10 females.
The age at which the last brain MRI or MRA was obtained ranged
from 7 days to 8 years 6 months, with the mean age of 2 years 1
month. Of the 24 patients, 21 underwent brain MRI without
contrast, two underwent brain MRA, and one underwent both brain
MRI without contrast and brain MRA. In addition to the 22q11.2
deletion, three patients had additional copy number variants of
unknown significance identified, including gains at 5q35.3 and
9p24.1, and loss at 15q11.2. The frequencies of medical comorbid-
ities in these 24 patients are shown in Table 1. The clinical features
of these patients were very similar to the general 22q11.2DS
population as reported in the literature. However, this patient
sample had more neurological issues.
Indications for brain imaging in the 24 patients are shown in
Figure 1. The most common indications were unexplained develop-
mental delay (6 of 24), seizures of unknown etiology (5 of 24), and
unilateral weakness (3 of 24). Two patients had imaging performed to
evaluate for aberrant vasculature and unspecified congenital anoma-
lies. Other indications occurred in one patient each and included
microcephaly, dysphagia, recurrent clubfoot, vertigo, hypoxemic-
ischemic insult, and headache.
Nearly half of the patients had abnormal head circumferences.
While 12 (50%) of 24 patients were normocephalic, 8 (33%) were
microcephalic, and 2 (8%) were macrocephalic (Table 2). No head
circumference data were available for the remaining 2 (8%) patients.
Interestingly, more than half of the patients with brain imaging had
remarkable findings (Table 3). The most common finding was
persistent cavum septi pellucidi and/or cavum vergae, seen in 8 of
24 (33%) patients. Aberrant cortical veins were seen in 6 (25%)
patients. These veins were considered abnormal due to their size,
number, or organization (Figure 2). Migrational disorders, such as
polymicrogyria and cortical dysplasia, were seen in 4 (17%) patients
(Figure 3a,b). Three (13%) patients had inner ear deformities that
consisted of vestibular dysplasia (Figure 4a,b). Lastly, 2 (8%) patients
had hypoplastic internal carotid arteries (Figure 5a,b), and 1 (4%)
patient had a hypoplastic cerebellum. It is important to note that 11
(46%) of 24 patients had no evidence of brain malformations.
TABLE 1 List of medical comorbidities and their relative frequency as compared to 22q11.2DS population
List of medical comorbidities
Number,
N = 24
Frequency of finding in
sample (%)
Frequency of finding in 22q11.2DS population (%)
(Bassett et al., 2005, 2011; Kobrynski & Sullivan, 2007;
Maggadottir & Sullivan, 2013)
Developmental delay and cognitive
impairment
20 83 75–90
Otolaryngologic 19 79 69–100
Neurological 19 79 8–40
Cardiovascular 16 67 49–83
Musculoskeletal 13 54 15–59
Immune-related 9 38 35–77
Genitourinary 6 25 10–37
Gastrointestinal 6 25 6–36
Psychiatric 5 21 9–50
Premature 4 17 –
Endocrine 4 17 17–60
Hematologic 2 8 6–30
Ophthalmologic 2 8 7–70
FIGURE 1 Indications for brain imaging. The top three
indications for brain imaging are developmental delay,
seizures, and unilateral weakness. [Color figure can be viewed at
wileyonlinelibrary.com]
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4 | DISCUSSION
The study herein describes 24 patients with genetically confirmed
22q11.2 deletion and brain MRI or MRA. The medical comorbidities
suggest that the 24 patients are a representative sample of the
22q11.2DS population. As seen in Table 1, the frequencies of medical
comorbidities in this patient sample fall within the ranges cited in the
literature, with the exception of neurological conditions. The
discrepancy seen amongst neurologic conditions likely stems from
inconsistent classification systems used in the literature. Other authors
may have used different classifications, leading to a lower overall
incidence of neurological findings in their cohorts of patients (Bassett
et al., 2005; Ryan et al., 1997). In order to be comprehensive, this study
did not limit neurologic conditions to structural abnormalities of the
brain, but also included spinal cord pathology, seizures, and neuro-
vascular abnormalities.
The other possibility is that the prevalence of neurological
abnormalities is underestimated since brain MRI, unlike renal
ultrasound and echocardiogram, is not routinely obtained in patients
with 22q11.2DS. In this sample, approximately 23% (26 of 111) of
patients with 22q11.2DS underwent brain MRI or MRA. There is no
previously published data on the percentage of patients, who undergo
brain imaging in this population. In comparison, renal ultrasound and
echocardiogram are recommended in all patients with 22q11.2DS at
the time of diagnosis (Bassett et al., 2011). This study elucidated
radiographic abnormalities, such as aberrant cortical veins and
vestibular dysplasia, that have not been previously identified in this
population.
A number of previous reports of neuroanatomical findings in
patients with 22q11.2DS were confirmed in this study. In this review,
four patients (17%) had evidence of migrational disorders, including
polymicrogyria and cortical dysplasia. Polymicrogyria, a developmental
malformation of neuronal migration resulting in deranged cortical layer
organization and excessive number of small gyri, was a significant
finding in 3 of 24 patients (Figure 3a). Despite the rarity of
polymicrogyria, it remains as one of the more common brain
malformations in patients with 22q11.2DS (Bingham et al., 1998;
Cramer et al., 1996; Ghariani et al., 2002; Kawame et al., 2000; Robin
et al., 2006).
The pathogenesis of polymicrogyria in 22q11.2DS remains
unclear, but a number of reports suggest a vascular mechanism
involving hypoperfusion of the brain (Robin et al., 2006). Haploinsuf-
ficiency of TBX1, a key gene deleted in the 22q11.2 region and
identified to be responsible for many of the cardiovascular phenotypes
in 22q11.2DS, was recently discovered to be involved in brain
angiogenesis in mice (Cioffi et al., 2014). Additionally, a range of
cardiac and Circle ofWillis anomalies have been described (Shprintzen,
2008). Schaer et al. (2009) report a correlation between reduced total
brain volume and gyrification in 22q11.2DS patients with significant
congenital cardiac disease.Of the three patientswith polymicrogyria in
this study, only one had cardiac defects. However, the possible
association of polymicrogyria with other comorbidities is not
adequately addressed here due to a small sample size.
The incidence of polymicrogyria in 22q11.2DS is estimated to
be 1% (McDonald-McGinn & Sullivan, 2011). The incidence of
TABLE 2 Head circumference
Number, N = 24
Frequency of




Data not available 2 8
TABLE 3 Brain MRI findings and their frequencies







Persistent cavum septi pellucidi
and/or cavum vergae
8 33
Aberrant cortical veins 6 25
Migrational disorders 4 17




Hypoplastic cerebellum 1 4
aPatients may present with more than one significant brain MRI finding.
FIGURE 2 Axial T2 FSE brain MRI demonstrating numerous small
caliber cortical veins (arrows) at the vertex. [Color figure can be
viewed at wileyonlinelibrary.com]
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polymicrogyria in the general population is unknown due to clinical
and radiographic heterogeneity. The clinical presentation depends
on extent and severity of cortical involvement, and may vary from
mild developmental delay to quadriplegia and intractable epilepsy.
Likewise, radiographic imaging is variable due to the type of
imaging modality, stage of maturity/myelination, and type of
polymicrogyria (Barkovich, 2010). Hence, subtle polymicrogyria
may be missed. Based on the positive finding in at least 3 of the
111 studied patients with 22q11.2DS, the incidence is estimated to
be at least 2.7%.
Cortical dysplasia, another neuronal migration abnormality, has
been reported in 22q11.2DS previously (Bird & Scambler, 2000).
Sprecher et al. (2005) demonstrated that the homozygous mutation of
synaptosome associated protein 29 (SNAP29), located outside the
1.5-Mb region but within the 3-Mb region of the 22q11.2 deletion, is
linked to cortical dysplasia in a rare autosomal recessive condition.
Severe cortical dysplasia was seen in one patient in this review;
however, aCGH demonstrated only a 1.4-Mb deletion.
This study demonstrates neurovascular findings previously
unidentified in patients with 22q11.2DS. In six patients, abnormal
cortical veins were seen. Two of these six patients also hadmigrational
disorders with abnormally enlarged cortical veins superficial to the
dysplastic cortex (Figure 3a). Similar findings have been reported in
patients with polymicrogyria and are useful adjuncts in making a
radiographic diagnosis of polymicrogyria (Hayashi, Tsutsumi, &
Barkovich, 2002). In the remaining four patients, the cortical veins,
in contrast, were smaller in caliber, abnormal in number, or
disorganized in appearance (Figure 2). The exact cause for this is
unclear, but it is speculated this may be due to an arrest in the
development and coalescence of microveins. Interestingly, three of
these four patients also had prominent extra-axial spaces or enlarged
ventricles. It has yet to be determined whether venous abnormalities
cause insufficient drainage, in turn causing prominent extra-axial
spaces or enlarged ventricles.
Additionally, arterial abnormalities were observed in some
patients. Two patients had unilateral hypoplastic internal carotid
FIGURE 3 Coronal T1 Flair brain MRI demonstrating perisylvian
polymicrogyria on the right (arrows) with a prominent
cortical vein (arrowhead) overlying the malformation (a). Sagittal
T1 brain MRI showing extensive cortical dysplasia (arrows)
involving frontal and temporal lobes (b). [Color figure can be
viewed at wileyonlinelibrary.com]
FIGURE 4 T2 FSE brain MRI showing lateral semicircular canal
dysplasia (arrows) in axial (a) and coronal (b) planes in one patient.
[Color figure can be viewed at wileyonlinelibrary.com]
FIGURE 5 Coronal T2 FSE brain MRI illustrating hypoplastic left
internal carotid artery (arrows) involving the terminus in one patient
(a) and the caverous segment in another patient (b). [Color figure
can be viewed at wileyonlinelibrary.com]
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arteries (ICA) at the carotid terminus or cavernous segment (Figure 5a,
b, respectively), and one of these patients also had polymicrogyria on
the ipsilateral side. It is not clear whether hypoperfusion of the brain
leads to polymicrogyria in these cases, but this association has been
suggested, as discussed earlier. Hypoplasia of the ICA can present as
cerebral ischemia or hemorrhage, and patients with this anomaly have
associated variations of the Circle of Willis, increased incidence of
intracranial aneurysms and extensive networks of collateral vessels to
compensate for the diminished carotid flow (Osborn, Mojtahedi, Hay,
& Dewitt, 1986).
Other findings included persistent cavum septi pellucidi and/or
cavum vergae, inner ear anomalies, and a hypoplastic cerebellum. In
this study, cavum septi pellucidi and/or cavum vergae were defined as
persistent if they were present on imaging after 6 months of age.
Persistent cavum septi pellucidi and/or cavum vergae, the most
common brain MRI findings in these patients, have been previously
reported in individuals with 22q11.2DS (Campbell et al., 2006; Chow
et al., 1999; Schmitt et al., 2014; Van Amelsvoort et al., 2001).
Hypoplastic cerebellum, as seen in one patient, has also been
demonstrated (Bish et al., 2006; Lynch et al., 1995; Mitnick et al.,
1994; Van Amelsvoort et al., 2001). Inner ear anomalies, such as
vestibular dysplasia (Figure 4a,b), were seen in three patients in this
case series. The significance of these inner ear anomalies is unclear.
None of these patients had sensorineural hearing loss. However, TBX1
has also been implicated in inner ear malformations in mice (Vitelli
et al., 2003).
The most common indications for brain imaging in these patients
together represented a majority (59%) of the patients with 22q11.2DS
and included unexplained developmental delay, seizures of unknown
etiology, and unilateral weakness. All the patients who underwent
imaging to evaluate for anatomical causes of developmental delays in
this study did so prior to their diagnosis of 22q11.2DS. In fact, the
detection of certain neuroanatomical abnormalities prompted further
genetic evaluation in some cases. For example, it is recommended that
FISH analysis for 22q11.2 be performed in all patients with perisylvian
polymicrogyria (Guerrini & Carrozzo, 2001). Conversely, patients with
a known diagnosis of 22q11.2DS and expected developmental delays
did not receive any brain imaging. Neuroimaging may be considered
when the degree of developmental delay exceeds normative
expectations for 22q11.2DS patients.
While seizures in 22q11.2DS are usually attributed to hypocalce-
mia or fever, seizures without a clear explanation may also be an
indication for neuroimaging. Undiagnosed brain abnormalities such as
cortical dysplasia can lower the seizure threshold in at risk patients.
ObtainingMRI would allow prognostication regarding the likelihood of
future seizures. Focal neurological findings manifested as unilateral
weakness (e.g., hemiparesis or unilateral facial palsy) may indicate a
localized brain lesion andwarrant further imaging asmedical or surgical
intervention may be needed to address underlying brain anomalies.
Limitations to this study include its retrospective nature and risk of
selection bias of the patient series. Patients with indications for brain
MRI (e.g., seizures, developmental delay, microcephaly, and unilateral
weakness) are more likely to have preexisting and previously
undetected neurological pathology. For example, patients with
polymicrogyria had a greater degree of developmental delay than is
typical for 22q11.2DS (Robin et al., 2006). However, the studied
patients as a group have developmental delay similar to that of the
general 22q11.2DS population. Another limitation of this study is the
potential for confounding bias in a few of the patients. Three patients
had copy number variants of unknown significance in addition to
22q11.2 deletion. The association between these genetic mutations
and the brain imaging findings is unknown.
By identifying patients with 22q11.2DS with neuroanatomical
abnormalities, early diagnosis and intervention may provide the best
opportunity to improve their clinical course. Patients with brain
malformations may require additional early childhood special educa-
tion, psychiatric evaluation and management, higher clinical suspicion
for seizures, or neurosurgical interventions. Also, the cluster of
radiographic findings in a patient without a prior diagnosis of
22q11.2DS, including cavum septi pellucidi and/or cavum vergae,
polymicrogyria or cortical dysplasia, inner ear anomalies, aberrant
cortical veins, hypoplastic internal carotid artery, and hypoplastic
cerebellum, should raise suspicion for 22q11.2DS and suggest referral
for a genetics evaluation.
5 | CONCLUSION
22q11.2 DS is a common genetic disorder with enormous phenotypic
heterogeneity. While there has been significant progress in identifying
brain malformations in patients with 22q11.DS, the implications of
those brain malformations is unclear. This study reveals the types and
frequencies of brain malformations, and suggests that the prevalence
of neurological anomalies may be underestimated in this population. A
better understanding of indications for imaging and frequently
encountered brain malformations will result in early diagnosis and
intervention in an effort to optimize patient outcomes.
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